Clinical trial
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in…
NCT00077636 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00077636 |
|---|---|
| Title | ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. |
| Official title | A Randomized, Open-label Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Copegus, peginterferon alfa-2a [Pegasys] |
| Enrollment | 1,469 |
| Start date | Dec 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Feb 13, 2004 |
| Last update posted | Feb 23, 2016 |
| Countries | Australia, Canada, France, Germany, Italy, New Zealand, Puerto Rico, Spain, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: